ZEVALIN Plus High Dose Chemotherapy Highly Effective in Aggressive Lymphoma
Spectrum Pharmaceuticals (Nasdaq: SPPI), today announced results of a randomized study comparing ZEVALIN (ibritumomab tiuxetan) injection for intravenous use plus high-dose BEAM chemotherapy vs. BEAM chemotherapy alone, published online by the journal “CANCER”, the Journal of the American Cancer Society. The paper, entitled “A Randomized Study Comparing Yttrium-90 Ibritumomab Tiuxetan and High-Dose BEAM Chemotherapy Versus BEAM Alone as the Conditioning Regimen Before Autologous Stem Cell Transplantation in Patients with Aggressive Lymphoma,”presented results from a study conducted by six centers in Israel, andwas authored by Avichai Shimoni, MD, Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.